BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Indivumed becomes Indivumed Therapeutics to advance Precision Oncology with Data and AI

After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics after the acqui...

April 05, 2023 | News

Leica Biosystems Strengthens Portfolio with FDA Clearance of Class II Mismatch Repair (MMR) Panel

Leica Biosystems announced the US Food and Drug Administration (FDA) 510(k) clearance of the BOND MMR Antibody Panel, providing customers with a high-perfo...

April 04, 2023 | News

Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights

Merck regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer Deal is the latest example of the company’...

March 30, 2023 | News

Thermo Fisher Scientific and Arsenal Biosciences Collaborate for T-Cell Therapy Manufacturing

ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for...

March 29, 2023 | News

3DHISTECH and Epredia Open Pathology Innovation Incubator to Accelerate Advancements in Cancer Diagnostics

The aim of the Pathology Innovation Incubator, founded by Epredia and 3DHISTECH, is to develop and improve solutions that revolutionize tumor diagnostics a...

March 27, 2023 | News

Cancer Research UK Funded Trial Finds that Chemotherapy Before Surgery Cuts the Risk of Colon Cancer from Returning

Led by the University of Birmingham and the University of Leeds, the Cancer Research UK-funded FOxTROT trial found that giving colon cancer patients c...

March 22, 2023 | News

Aptamer launches Optimer®-Fc as a new reagent solution for immunohistochemistry

Two top 10 pharma companies are seeking to trial Optimer-Fc for IHC Aptamer is currently working with one of the top three IHC companies to validate the...

March 21, 2023 | News

BioNTech and OncoC4 to Co-Develop and Commercialize Novel Checkpoint Antibody for Solid Tumor Treatment

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), a clinical-stage biopharmaceutical company dedicated...

March 20, 2023 | News

Etana has secured financing from Deg, East Ventures and other global investors

Etana is committed to build production capacity for mammalian cell for monoclonal antibodies drug substance to ensure high local content production a...

March 20, 2023 | News

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

ADC drugs have the advantages of highly specific targeting of antibody and anti cancer activity of cytotoxin. ADC shave developed rapidly as tumor therapeu...

March 16, 2023 | News

Pfizer Invests $43 Billion to Battle Cancer

Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfiz...

March 14, 2023 | News

Porton Advanced and Bennu Biotherapeutics Partner to Develop Cell Therapy for Solid Tumors

As an end-to-end gene and cell therapy service CDMO, Porton Advanced provides comprehensive solutions covering plasmids, cell therapy, gene therapy, oncoly...

March 13, 2023 | News

TransCure bioServices delivers CDX mouse models to advance AML preclinical studies

TransCure bioServices has developed cell line-derived xenograft (CDX) mouse models that will change how researchers tackle the preclinical studies of cance...

March 07, 2023 | News

Prenetics Forms Advisory Board for Precision Oncology Strategy

Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Adviso...

March 02, 2023 | News

Stay Connected